Revolver Therapeutics secures £572k for peptide-based cancer inhibitors

Targeting proteins often considered undruggable, Revolver Therapeutics Limited has raised £572.6k in its latest funding round. The Bath-based company focuses on oncology by developing peptide-based inhibitors that target transcription factors involved in cancer development. This investment brings the business to an estimated post-money valuation of £1.9m.

Incorporated in 2023, the startup addresses difficult-to-treat conditions, with an initial focus on childhood gliomas. Its proprietary screening platform allows for the rapid evaluation of millions of peptides to identify functional inhibitors. The technology is also being explored for applications in various adult cancers.

Financial records for the year ended 28 February 2025 show the company employed three people, though more recent data suggests the headcount has grown to four. Michelle Marie Law was appointed as a director during the same month as the share allotment (June 2026).